Vanguard Group Inc. Has $67.73 Million Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Vanguard Group Inc. boosted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,068,246 shares of the company's stock after buying an additional 18,716 shares during the quarter. Vanguard Group Inc. owned approximately 3.59% of Disc Medicine worth $67,727,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of IRON. Teacher Retirement System of Texas raised its holdings in shares of Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock valued at $400,000 after purchasing an additional 593 shares in the last quarter. Rhumbline Advisers increased its stake in Disc Medicine by 5.7% in the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company's stock valued at $1,841,000 after buying an additional 1,553 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Disc Medicine by 16.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock worth $799,000 after buying an additional 2,257 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Disc Medicine by 66.0% during the 4th quarter. SG Americas Securities LLC now owns 8,076 shares of the company's stock worth $512,000 after buying an additional 3,212 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, insider Pamela Stephenson sold 3,137 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the transaction, the insider now directly owns 69,529 shares in the company, valued at approximately $3,794,892.82. This represents a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 5,574 shares of Disc Medicine stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the completion of the sale, the chief executive officer now owns 154,828 shares of the company's stock, valued at $8,450,512.24. This trade represents a 3.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 361,690 shares of company stock worth $19,648,094 in the last 90 days. Company insiders own 4.24% of the company's stock.

Disc Medicine Stock Performance

Shares of IRON stock traded up $0.25 during midday trading on Tuesday, hitting $40.52. 180,748 shares of the company were exchanged, compared to its average volume of 345,636. The firm has a market capitalization of $1.40 billion, a P/E ratio of -10.18 and a beta of 0.77. Disc Medicine, Inc. has a 52 week low of $25.64 and a 52 week high of $68.73. The firm's 50 day moving average price is $50.57 and its two-hundred day moving average price is $55.51.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.08. Analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on IRON. Stifel Nicolaus upped their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, January 24th. Cantor Fitzgerald upped their price objective on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Morgan Stanley restated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a report on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.